15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      IL-15 enhances the antitumor effect of human antigen-specific CD8 + T cells by cellular senescence delay

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Optimal expansion protocols for adoptive human T-cell therapy often include interleukin (IL)-15; however, the mechanism by which IL-15 improves the in vivo antitumor effect of T cells remains to be elucidated. Using human T cells generated from HLA-A2+ donors against novel T-cell epitopes derived from the human U266 myeloma cell line Ig light chain V-region (idiotype) as a model, we found that T cells cultured with IL-15 provided superior resistance to tumor growth in vivo, compared with IL-2, after adoptive transfer into immunodeficient hosts. This effect of IL-15 was associated with delayed/reversed senescence in tumor antigen-specific memory CD8 + T cells mediated through downregulation of P21 WAF1, P16 INK4a, and P53 expression. Compared to IL-2, IL-15 stimulation dramatically activated JAK3-STAT5 signaling and inhibited the expression of DNA damage genes. Thus, our study elucidates a new mechanism for IL-15 in the regulation of STAT signaling pathways and CD8 + T-cell senescence.

          Related collections

          Author and article information

          Journal
          Oncoimmunology
          Oncoimmunology
          KONI
          koni20
          Oncoimmunology
          Taylor & Francis
          2162-4011
          2162-402X
          2016
          7 October 2016
          : 5
          : 12
          : e1237327
          Affiliations
          [a ] Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center , Houston, TX, USA
          [b ] Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University , Guangzhou, China
          [c ] Department of Immunology, The University of Texas MD Anderson Cancer Center , Houston, TX, USA
          Author notes
          CONTACT Jinsheng Weng, M.D., Ph.D jweng@ 123456mdanderson.org , jweng35@ 123456yahoo.com Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , 7455 Fannin Street, Houston, TX 77030, USA, Department of Center Laboratory, The Fifth Affiliated Hospital of Guangzhou Medical University , Guangzhou, 510700, China

          Supplemental data for this article can be accessed on the publisher's website.

          Author information
          https://orcid.org/0000-0002-1664-5386
          https://orcid.org/0000-0003-4763-4409
          Article
          PMC5215241 PMC5215241 5215241 1237327
          10.1080/2162402X.2016.1237327
          5215241
          28123872
          43df4893-d062-4d7b-b9b1-b74daae0e032
          © 2016 Taylor & Francis Group, LLC
          History
          : 20 April 2016
          : 31 August 2016
          : 10 September 2016
          Page count
          Figures: 4, Tables: 1, References: 73, Pages: 12
          Categories
          Original Research

          T cells,Idiotype,IL-15,immunotherapy,myeloma,senescence
          T cells, Idiotype, IL-15, immunotherapy, myeloma, senescence

          Comments

          Comment on this article